Results 121 to 130 of about 16,238 (237)

Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial [PDF]

Janghee Woo, Tingting Zhai, Fang Yang, Huilei Xu, Margaret L. Healey, Denise P. Yates, Michael T. Beste, David P. Steensma   +7 more
openalex   +2 more sources

Canakinumab for Adult-Onset Still Disease

, 2023
Khai Tran, Monika Mierzwinski‐Urban
openalex   +2 more sources

Canakinumab and Lung Cancer: Intriguing, but Is It Real? [PDF]

, 2018
Bruce A. Chabner, Christopher S. Nabel
openalex   +1 more source

5PSQ-074 Canakinumab in familial mediterranean fever and secondary amyloidosis: a case report [PDF]

, 2019
V González Rosa, MI Sierra Torres, S Fernández Espínola, M Zaragoza Rascón, M Pajares Alonso   +4 more
openalex   +1 more source

Microcrystals as DAMPs and their role in joint inflammation [PDF]

, 2017
Microcrystals associated with joint diseases, namely monosodium urate, calcium pyrophosphate and basic calcium phosphate, can be considered as ‘danger signals' to the innate immune system and provoke inflammation through inflammasome-dependent as well as
Busso, Nathalie, So, Alexander
core  

Treatment of systemic-onset juvenile arthritis with canakinumab

Open Access Rheumatology: Research and Reviews, 2015
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the ...
Peitz J, Horneff G
doaj  

CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)

, 2019
Luis Paz‐Ares, Edward B. Garon, Andrea Ardizzoni, Fabrice Barlési, Byoung Chul Cho, Gilberto de Castro, Pedro De Marchi, Enriqueta Felip, Y. Goto, Alastair Greystoke, Shun Lü, Wan‐Teck Lim, Vassiliki A. Papadimitrakopoulou, Martin Reck, Benjamin Solomon, David R. Spigel, Daniel S.W. Tan, Michael Thomas, James Chih‐Hsin Yang, Bruce E. Johnson   +19 more
openalex   +1 more source

OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40 [PDF]

, 2017
Fabrizio De Benedetti, Marco Gattorno, Joost Frenkel, Inmaculada Calvo, Michel Moutschen, Pierre Quartier, Özgür Kasapçopur, Seza Özen, Ahmet Gül, Jordi Antón, Isabelle Koné‐Paut, Helen J. Lachmann, HM Hoffman, Eldad Ben‐Chetrit, Andrew Zeft, Yifan Gong, Eleni Vritzali, G. Junge   +17 more
openalex   +1 more source

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. [PDF]

, 2015
BACKGROUND: To investigate potential cardiovascular and other effects of long-term pharmacological interleukin 1 (IL-1) inhibition, we studied genetic variants that produce inhibition of IL-1, a master regulator of inflammation.
Interleukin 1 Genetics Consortium
core  

Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade

JACC: Advances
Background: Serum urate (SU) associates with cardiovascular (CV) events, mortality, and gout. Objectives: The purpose of this study was to assess whether SU predicts CV risk in a trial of interleukin (IL)-1β inhibition with canakinumab, and whether IL-1β
Nicholas H. Adamstein, MD, Jean G. MacFadyen, BA, Brittany N. Weber, MD, PhD, Peter Libby, MD, Daniel H. Solomon, MD, MPH, Paul M Ridker, MD, MPH   +5 more
doaj   +1 more source